- Home
- QLGN
as 07-26-2024 4:00pm EST
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CALIFORNIA |
| Market Cap: | 2.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 36.2M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.14 - $1.26 | Next Earning Date: | 08-13-2024 |
| Revenue: | $1,627,031 | Revenue Growth: | 13.74% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Qualigen Therapeutics Inc. News
QLGN Breaking Stock News: Dive into QLGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
25 days ago
Lifecore Biomedical Announces Cooperation Agreement with 22NW
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
Bloomberg
2 months ago
Macron Calls French Legislative Election After Far-Right Surge
AFP
2 months ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Compare QLGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QLGN Qualigen Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.